Toxic effects and use of therapeutic monoclonal antibodies;Les complications « toxiques » liées à l'utilisation des anticorps monoclonaux

Medecine/Sciences

Volumn 25, Issue 12, 2009, Pages 1130-1134

  Pallardy, Marc ^a  

^a UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMALIA;

ANTIIDIOTYPIC ANTIBODY; CYTOKINE; MONOCLONAL ANTIBODY;

ANIMAL; AUTOIMMUNE DISEASE; BIOSYNTHESIS; CARDIOMYOPATHY; CHEMICALLY INDUCED DISORDER; DRUG DELIVERY SYSTEM; DRUG ERUPTION; DRUG SCREENING; GASTROINTESTINAL DISEASE; HUMAN; IMMUNE COMPLEX DISEASE; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; OPPORTUNISTIC INFECTION; REVIEW; SECRETION;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; AUTOIMMUNE DISEASES; CARDIOMYOPATHIES; CYTOKINES; DRUG DELIVERY SYSTEMS; DRUG ERUPTIONS; DRUG EVALUATION, PRECLINICAL; GASTROINTESTINAL DISEASES; HUMANS; IMMUNE COMPLEX DISEASES; IMMUNOSUPPRESSION; MICE; OPPORTUNISTIC INFECTIONS;

EID: 74749083620     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.1051/medsci/200925121130     Document Type: Review

References (20)

1. Gerber HP, Ferrara N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapies in preclinical studies. Cancer Res 2005 ; 65 : 671-80.
2. Hurwitz H, Saini S. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events. Semin Oncol 2006 ; 33 : S26-34.
3. Hodi FS, Butler M, Oble DA, et al. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci USA 2008 ; 105 : 3005-10.
4. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4. J Clin Oncol 2006 ; 24 : 2283-9.
5. Tabrizi MA, Roskos LK. Preclinical and clinical safety of monoclonal antibodies. Drug Discov Today 2007 ; 12 : 540-7.
6. Saif MW, Kim R. Incidence and management of cutaneous toxicities associated with cetuximab. Expert Opin Drug Saf 2007 ; 6 : 175-82.
7. Cook-Bruns, R. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer. Oncology 2001 ; 61 : 58-66.
8. Bria E, Cuppone F, Milella M, et al. Trastuzumab cardiotoxicity: biological hypotheses and clinical open issues. Expert Opin Biol Ther 2008 ; 8 : 1963-71.
9. 111Indium-trastuzumab visualises myocardial human epidermal growth factor receptor 2 expression shortly after anthracycline treatment but not during heart failure: a clue to uncover the mechanisms of trastuzumab-related cardiotoxicity. Eur J Cancer 2007 ; 43 : 2046-51.
10. Winkler U, Jensen M, Manzke O, et al. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8). Blood 1999 ; 94 : 2217-24.
11. Wing MG, Moreau T, Greenwood J, et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 1996 ; 98 : 2819-26.
12. Chatenoud L, Ferran C, Legendre C, et al. In vivo cell activation following OKT3 administration. Systemic cytokine release and modulation by corticosteroids. Transplantation 1990 ; 49 : 697-702.
13. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006 ; 355 : 1018-28.
14. Chatenoud L, Bluestone JA. CD3-specific antibodies: a portal to the treatment of autoimmunity. Nat Rev Immunol 2007 ; 7 : 622-32.
15. Suntharalingam G, Perry MR, Ward S, et al. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006 ; 355 : 1018-28.
16. Stebbings R, Findlay L, Edwards C, et al. Cytokine storm in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics. J Immunol 2007 ; 179 : 3325-31.
17. Müller N, van den Brandt J, Odoardi F, et al. A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats. J Clin Invest 2008 ; 118 : 1405-16.
18. Baudouin V, Crusiaux A, Haddad E, et al. Anaphylactic shock caused by immunoglobulin E sensitization after retreatment with the chimeric anti-interleukin-2 receptor monoclonal antibody basiliximab. Transplantation 2003 ; 76 : 459-63.
19. Johansson A, Erlandsson A, Eriksson D, et al. Idiotypic-anti- idiotypic complexes and their in vivo metabolism. Cancer 2002 ; 94 : 1306-13.
20. st 2007. http://www.emea.europa.eu/pdfs/human/swp/2836707enfin.pdf